Crossmark

Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry

Crossref DOI link: https://doi.org/10.1186/s12883-019-1304-8

Published Online: 2019-05-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cowen, Leslie

Mancini, Maria

Martin, Ann

Lucas, Ann

Donovan, Joanne M.
Funding

Funding for this research was provided by:

Catabasis Pharmaceuticals (NA)

Parent Project Muscular Dystrophy (NA)
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

Received: 10 December 2018

Accepted: 15 April 2019

First Online: 2 May 2019

Ethics approval and consent to participate

: Written informed consent from participants or their parents/guardians was obtained in compliance with all local laws and regulations, and institutional investigational review board or ethics committee approval. The Duchenne Registry and electronic consent are approved by the Geisinger Institutional Review Board (Geisinger Medical Center, Danville, PA, IRB#2014–0621).

: Not applicable.

: LC, MM and JD are employees of Catabasis Pharmaceuticals, the study sponsor, which is developing an investigational drug, edasalonexent, for treatment of Duchenne muscular dystrophy, which is being studied in patients not on corticosteroids.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.